AstraZeneca and GlaxoSmithKline both have reported the trial results which could likely help make their medicines available to an increased no. of patients with ovarian cancer. This will possibly help GSK get ahead of its competitors in the highly contested medicine category.
On Saturday, both the firms announced separately their respective medicines prevented the ovarian cancer to come back in women, thus lowering a relapse risk.
AstraZeneca along with Merck & Co., its US manufacturing partner said that their drug Lynparza reduced the rate of ovarian cancer, progressing by 41 percent again. The figure stood at 38 percent for GSK’s medicine.
Both the firms said that they would be discussing the results along with healthcare regulators to make the drugs available at a broader level.
Analysts have witnessed Lynparza lead, having an average $3.1bn sales estimate for 2023. Meanwhile, GSK’s Zejula drug is observed to attain around $1.1bn in sales that year. However, distinct trial settings would make it tough for the physicians to predict the effect of these two drugs.
On the other hand, other drugs like Rubracaand Pfizer’s Talzennaare seen to be further behind with regards to future revenue perspective. Currently, Abbvie is conducting tests on an experimental element known as veliparib.